Therapeutic effects of pegylated-interferon (Peg-IFN) therapy combined with ribavirin (RBV) and simeprevir on patients with chronic hepatitis C

Therapeutic effects of pegylated-interferon (Peg-IFN) therapy combined with ribavirin (RBV) and simeprevir on patients with chronic hepatitis C - Investigation of the therapeutic effects regarding a new triple therapy for chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013715

Enrollment

Registered

2014-04-14

Start date

2013-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Peg-IFN-alpha2a/RBV/simeprevir 12weeks plus Peg-IFN-alpha2a/RBV 36weeks: a total of 48 weeks treatment Peg-IFN-alpha2a/RBV/simeprevir 12weeks plus Peg-IFN-alpha2a/RBV 36weeks: a total of 48 weeks tr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients having genotype 1b high virus titer chronic hepatitis C (HCV-RNA more than 5 LogIU/mL) who did not achieve early viral response and failed in viral eradication with the previous Peg-IFN plus RBV treatment and who met the following inclusion criteria: laboratory data before study treatment of white blood cell count over 3,000/mm3, neutrophil count over 1,500/mm3,platelet count over 90,000/mm3, and hemoglobin over 12 g/dL

Exclusion criteria

Exclusion criteria: Patients who did not fulfill the criteria to receive the approved Peg-IFN-alpha/RBV/simeprevir treatment

Design outcomes

Primary

Measure	Time frame
The rate of sustained viral response (having undetectable serum HCV-RNA 24 weeks after the end of treatment)	—

Countries

Japan

Contacts

Public ContactHirayuki Enomoto

Hyogo College of Medicine Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine

enomoto@hyo-med.ac.jp0798-45-6472

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026